The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid colorimetric assay for cell growth and survival
Denizot, F., & Lang, R. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90368-6 · Cited by 4,935
Biodegradable polymeric nanoparticles based drug delivery systems
Kumari, A., Yadav, S. K., & Yadav, S. C. (2010) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2009.09.001 · Cited by 3,724
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882
Structural Classification of Toxic Amyloid Oligomers
Glabe, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800016200 · Cited by 783
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676 · cited 1×
“Ab1-42 is the predominant species of Ab peptide (approximately 96% the total) [11] and its monomer is the most toxic isoform because it has a strong tendency toward aggregation [12], although its protofibrillar and fibrillar aggregates are also toxic [13,14].”
BackgroundBlood brain barrier: ageing and microvascular disease-systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.089 · Cited by 639
McDonnell, J. M. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00251-9 · Cited by 594
Advances in the early detection of Alzheimer's disease
Nestor, P. J., Scheltens, P., & Hodges, J. R. (2004) · Nature Medicine · doi:10.1038/nrn1433 · Cited by 463
Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease
Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., Wu, A., Mallikarjuana, N. N., Manohar, S., Liang, H.-F., Kulkarni, A. R., et al. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.024 · Cited by 406
Surface Plasmon Resonance: Applications in Understanding Receptor–Ligand Interaction
Pattnaik, P. (2005) · Applied Biochemistry and Biotechnology · doi:10.1385/abab:126:2:079 · Cited by 364
Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
Townsend, M., Mehta, T., & Selkoe, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610390200 · Cited by 318
Targeting the brain with PEG–PLGA nanoparticles modified with phage-displayed peptides
Li, J., Feng, L., Fan, L., Zha, Y., Guo, L., Zhang, Q., Chen, J., Pang, Z., Wang, Y., Jiang, X., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.031 · Cited by 296
Self-citationBrown, R. C., Morris, A. P., & O'Neil, R. G. (2007) · Brain Research · doi:10.1016/j.brainres.2006.10.083 · Cited by 291
Zhang, Q., Jiang, X., Jiang, W., Lu, W., Su, L., & Shi, Z. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.01.039 · Cited by 286
Self-citationPrecise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles
Gao, H., Qian, J., Cao, S., Yang, Z., Pang, Z., Pan, S., Fan, L., Xi, Z., Jiang, X., & Zhang, Q. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.058 · Cited by 280
Self-citationAllaman, I., Gavillet, M., Bélanger, M., Laroche, T., Viertl, D., Lashuel, H. A., & Magistretti, P. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5098-09.2010 · Cited by 278
Omidi, Y., Campbell, L., Barar, J., Connell, D., Akhtar, S., & Gumbleton, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03443-7 · Cited by 246
Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease
Crouch, P. J., Harding, S.-M. E., White, A. R., Camakaris, J., Bush, A. I., & Masters, C. L. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.07.013 · Cited by 244
Alzheimer's disease drug development and the problem of the blood‐brain barrier
Pardridge, W. M. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.06.003 · Cited by 203
Yan, H., Wang, L., Wang, J., Weng, X., Lei, H., Wang, X., Jiang, L., Zhu, J., Lu, W., Wei, X., et al. (2012) · ACS Nano · doi:10.1021/nn203749v · Cited by 191
Brambilla, D., Verpillot, R., Le Droumaguet, B., Nicolas, J., Taverna, M., Kóňa, J., Lettiero, B., Hashemi, S. H., De Kimpe, L., Canovi, M., et al. (2012) · ACS Nano · doi:10.1021/nn300489k · Cited by 188
[13] Methodological and chemical factors affecting amyloid β peptide amyloidogenicity
Zagorski, M. G., Yang, J., Shao, H., Ma, K., Zeng, H., & Hong, A. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)09015-1 · Cited by 185
Wiesehan, K., Buder, K., Linke, R. P., Patt, S., Stoldt, M., Unger, E., Schmitt, B., Bucci, E., & Willbold, D. (2003) · ChemBioChem · doi:10.1002/cbic.200300631 · Cited by 171
Progressive brain dysfunction following intracerebroventricular infusion of beta1–42-amyloid peptide
Nakamura, S., Murayama, N., Noshita, T., Annoura, H., & Ohno, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02704-4 · Cited by 166
Gralle, M., Caarls, M. B., & Wouters, F. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808755200 · Cited by 150
Winkler, J., Ramirez, G. A., Kuhn, H. G., Peterson, D. A., Day-Lollini, P. A., Stewart, G. R., Tuszynski, M. H., Gage, F. H., & Thal, L. J. (1997) · Annals of Neurology · doi:10.1002/ana.410410114 · Cited by 145
Estimation of Variance for AUC in Animal Studies
Yuan, J. (1993) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600820718 · Cited by 143
Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (−) prostate cancers
Min, K., Jo, H., Song, K.-M., Cho, M., Chun, Y., Jon, S., Kim, W. J., & Ban, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.035 · Cited by 137
Wang, F., Jiang, X., & Lu, W. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00341-7 · Cited by 120
Huile, G., Pan, S., Yang, Z. H., Cao, S., Chen, C., Xin-guo, J., Shun, S., Zhiqing, P., & Yu, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.069 · Cited by 117
Christensen, R., Marcussen, A. B., Wörtwein, G., Knudsen, G. M., & Aznar, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.10.009 · Cited by 117
Chen, J., Zhang, C., Liu, Q., Shao, X., Feng, C., Shen, Y., Zhang, Q., & Jiang, X. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2011.622396 · Cited by 103
Self-citationAmyloid Angiopathy and Blood–Brain Barrier Changes in Alzheimer's Disease a, b
Wı́sniewski, H. M., VORBRODT, A. W., & WEGIEL, J. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48468.x · Cited by 99
β-Amyloid Production, Aggregation, and Clearance as Targets for Therapy in Alzheimer's Disease
Felice, F. G. D., & Ferreira, S. T. (2002) · Cellular and Molecular Neurobiology · doi:10.1023/a:1021832302524 · Cited by 91
van Groen, T., Kadish, I., Wiesehan, K., Funke, S. A., & Willbold, D. (2008) · ChemMedChem · doi:10.1002/cmdc.200800289 · Cited by 73
Surface plasmon resonance in monitoring of complement activation on biomaterials
Arima, Y., Toda, M., & Iwata, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.018 · Cited by 35
Differently Selected d -Enantiomeric Peptides Act on Different Aβ Species
Bartnik, D., Funke, S. A., Andrei‐Selmer, L., Bacher, M., Dodel, R. C., & Willbold, D. (2009) · Rejuvenation Research · doi:10.1089/rej.2009.0924 · Cited by 27
Early detection of Alzheimer disease: 11 C-PiB PET in twins discordant for cognitive impairment
Scheinin, N. M., Aalto, S., Kaprio, J. A., Koskenvuo, M., Räihä, I. J., Rokka, J., Hinkka‐Yli‐Salomäki, S., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318225118e · Cited by 26
The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease
Ling, S., Zhou, J., Rudd, J. A., Hu, Z., & Fang, M. (2011) · The Anatomical Record · doi:10.1002/ar.21425 · Cited by 18
Enhanced procedural learning following beta-amyloid protein (1-42) infusion in the rat
Ammassari‐Teule, M., Middei, S., Passino, E., & Restivo, L. (2002) · Neuroreport · doi:10.1097/00001756-200209160-00022 · Cited by 18
Dementia and Alzheimer’s Disease
Barnes, D. E., López, O. L., & Yaffe, K. S. (2012) · Springer eBooks · doi:10.1007/978-94-007-5061-6_31 · Cited by 12
Dementia and Alzheimer's disease
(2011) · Elsevier eBooks · doi:10.1016/b978-0-7295-3908-1.10011-9 · Cited by 3
Cited by
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Metadata
- Authors
- Zhang, C., Wan, X., Zheng, X., Shao, X., Liu, Q., Zhang, Q., & Qian, Y.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 35
- Issue
- 1
- Pages
- 456-465
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2085800477
- Cited by
- 262
- References
- 42
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.